New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

September 11, 2024

A new research study evaluates advanced diagnostic and prognostic tools for feline lymphoma and how they can complement existing tests.

--

This article is written by Emily Singler and published in AAHA NEWStat.

--

Feline lymphoma can be a challenging disease to diagnose for many reasons. According to Ira Gordon, DVM, DACVR-RO, radiation oncologist and former specialty practice owner, much of the challenge with diagnosing lymphoma in cats has to do with its variability in presentation. Whereas the most common clinical presentation in dogs with lymphoma is peripheral lymphadenopathy, Gordon reports that cats rarely present this way. Instead, he said, “many cases of feline lymphoma arise in places that are difficult to sample or biopsy,” such as the gastrointestinal tract, the kidneys, and the mediastinum. Furthermore, many cases of feline lymphoma are small cell, making them difficult to differentiate from other non-neoplastic conditions based on cytology.  

ImpriMed, a biotechnology company pairing laboratory techniques with cutting edge artificial intelligence (AI), recently reported on their work to help mitigate some of these concerns. Published in the journal Veterinary Sciences in July 2024, their article describes flow cytometry and as a “reliable and useful method for characterizing feline lymphomas,” citing 82-90% concordance with cytology, which the researchers refer to as the gold standard (along with histology for solid tissue) for lymphoma diagnosis.

Ilona Holcomb, PhD, ImpriMed’s Director of Bioscience, explains that the company’s original focus was canine lymphoma. Their aim was to improve diagnostic and prognostic capabilities for veterinarians through the combination of advanced laboratory techniques and “real world clinical outcome data” to train advanced AI models. This has included flow cytometry panels, PCR for antigen receptor rearrangement (PARR), and drug response predictions (powered by AI) to determine which chemotherapy drugs would work best for a given patient, a true “personalized medicine tool” according to Holcomb.  

These assays are also available for canine leukemias, and flow cytometry and PARR are now offered for characterization of feline lymphomas and leukemias.  

The benefits and limitations of flow cytometry and PARR

Flow cytometry involves suspending cells in liquid, passing them through a laser-based light source and then measuring the resultant scattering of light to draw conclusions about the cells’ relative size (small, medium, or large), granularity, and subtype (or immunophenotype), namely B cell or T cell for lymphocytes.  

PARR involves extracting and amplifying cell DNA to look for antigen receptor genes that code for either immunoglobulins (in B cells) or T cell receptors (in T cells). Identifying a homogenous population of antigen receptor genes (also termed clonality) can help differentiate neoplasia from reactive lymphocytes and determine the difference between B cell and T cell lymphomas to provide important prognostic and treatment insight.  

A variety of sample types, including lymph node aspirates, blood samples, and solid tissue samples, can be used for flow cytometry and PARR, provided an adequate amount of the cells of interest are present in the given sample. In the case of lymph node aspirates, multiple aspirations may be needed to obtain a sufficient number of cells (typically about a million cells are needed according to Holcomb).  

Holcomb clarified that she considers flow cytometry paired with PARR to be diagnostic support tools, whereby they are used to complement the results obtained by cytology/histology. Gordon echoed this sentiment: “PARR or flow cytometry should not be used as stand-alone tests in screening or diagnosing lymphoma but are useful ancillary tests when initial diagnostics are inconclusive or incomplete.” He added that a subset of cats with lymphoma may benefit from the additional prognostic information gained from these tests, although more research is needed to identify which cases would fit in this category.

Opportunities for further study and advancement

While it is already commercially available for canine lymphomas and leukemias, ImpriMed’s drug response prediction technology for feline lymphoma and leukemia is still being refined. Their hope is that it will be as informative for the treatment of cats as it has been for dogs. One of the challenges with cats, Holcomb says, is that they tend to be treated with fewer chemotherapy drugs at a time when compared to dogs. This has created a challenge in building a robust database of real-world outcome data from which their AI algorithms can draw conclusions and make predictions.  

Holcomb also reports that it is more difficult to make prognostic predictions and treatment recommendations for medium or intermediate cell lymphoma. Whereas small cell and large cell lymphomas have more well-known prognostic indicators and evidence-based treatment recommendations that can be made, medium cell lymphoma is less understood. She hopes that with continued research and AI training, they will be better able to predict treatment outcomes for this uncommon lymphoma subtype.

Encouragement from an oncologist

It can be easy to get discouraged by what we don’t know and what we still have yet to accomplish in our understanding of lymphoma in cats. “It is clear that feline lymphoma encompasses many diseases rather than a single entity,” Gordon said. He also commented that veterinary medicine is lagging “far behind” human medicine in the ability to diagnose and characterize lymphoma in cats.  Flow cytometry and PARR, however, represent a “significant step forward,” Gordon added. And while there is much to still be learned, he argues that it’s important that we not be afraid to take advantage of new diagnostic tools, even in their earlier stages. “As with all novel medical products, it will take robust clinical use and additional research to maximize our knowledge and their value,” he said. “If we are too slow to adopt them, companies will take them off of the market and our patients will be unable to benefit from them.”

Further reading:

Prognostic Utility of the Flow Cytometry and Clonality Analysis Results for Feline Lymphomas

Flow cytometry for feline lymphoma article in J Feline Med Surg

Feline lymphoma: diagnosis, staging and clinical presentations

Photo credit: Images we create and what actually happens are always beautiful when we have imagination/iStock via Getty Images Plus

Disclaimer: The views expressed, and topics discussed, in any NEWStat column or article are intended to inform, educate, or entertain, and do not represent an official position by the American Animal Hospital Association (AAHA) or its Board of Directors.

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →